Zimmer Biomet Holdings 将来の成長

Future 基準チェック /26

Zimmer Biomet Holdings利益と収益がそれぞれ年間15.9%と5.1%増加すると予測されています。EPS は年間増加すると予想されています。自己資本利益率は 3 年後に13.9% 14.9%なると予測されています。

主要情報

15.9%

収益成長率

14.90%

EPS成長率

Medical Equipment 収益成長	12.7%
収益成長率	5.1%
将来の株主資本利益率	13.85%
アナリストカバレッジ	Good
最終更新日	01 Oct 2025

今後の成長に関する最新情報

Recent updates

Zimmer Biomet Holdings (NYSE:ZBH) Shareholders Will Want The ROCE Trajectory To Continue

May 27

Some May Be Optimistic About Zimmer Biomet Holdings' (NYSE:ZBH) Earnings

May 12

An Intrinsic Calculation For Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Suggests It's 39% Undervalued

Apr 09

Zimmer Biomet Holdings (NYSE:ZBH) Has Announced A Dividend Of $0.24

Mar 15

Zimmer Biomet Holdings (NYSE:ZBH) Has Announced A Dividend Of $0.24

Mar 01

Zimmer Biomet: Adding To The Growth Profile

Feb 07

Investors Appear Satisfied With Zimmer Biomet Holdings, Inc.'s (NYSE:ZBH) Prospects

Feb 06

These 4 Measures Indicate That Zimmer Biomet Holdings (NYSE:ZBH) Is Using Debt Reasonably Well

Jan 10

Zimmer Biomet: Back On Offense With Strong Cash Flow Outlook

Jan 05

Zimmer Biomet Holdings (NYSE:ZBH) Is Due To Pay A Dividend Of $0.24

Dec 21

At US$108, Is It Time To Put Zimmer Biomet Holdings, Inc. (NYSE:ZBH) On Your Watch List?

Dec 08

Shareholders Can Be Confident That Zimmer Biomet Holdings' (NYSE:ZBH) Earnings Are High Quality

Nov 07

Results: Zimmer Biomet Holdings, Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates

Nov 02

Zimmer Biomet: The Undervalued Titan Of Joint Replacements

Oct 02

Zimmer Biomet Stock: Don't Jump In At The 52-Week Low

Sep 19

Zimmer Biomet: Brighter Prospects In H2 2024

Jul 02

Zimmer Biomet Holdings: Moving Along

May 17

業績と収益の成長予測

NYSE:ZBH - アナリストの将来予測と過去の財務データ ( )USD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2027	9,095	1,339	1,726	2,056	18
12/31/2026	8,684	1,012	1,636	1,829	25
12/31/2025	8,217	832	1,100	1,590	26
6/30/2025	7,834	824	1,151	1,663	N/A
3/31/2025	7,699	913	1,131	1,654	N/A
12/31/2024	7,679	904	902	1,499	N/A
9/30/2024	7,596	1,084	1,014	1,582	N/A
6/30/2024	7,525	997	844	1,523	N/A
3/31/2024	7,452	964	759	1,502	N/A
12/31/2023	7,394	1,024	875	1,582	N/A
9/30/2023	7,279	474	548	1,237	N/A
6/30/2023	7,196	506	724	1,351	N/A
3/31/2023	7,108	450	858	1,355	N/A
12/31/2022	6,940	290	809	1,285	N/A
9/30/2022	6,892	366	970	1,406	N/A
6/30/2022	6,908	334	957	1,389	N/A
3/31/2022	6,889	325	1,078	1,490	N/A
12/31/2021	6,827	445	1,074	1,499	N/A
9/30/2021	7,135	834	1,164	1,559	N/A
6/30/2021	7,379	914	1,132	1,507	N/A
3/31/2021	6,842	563	618	1,000	N/A
12/31/2020	6,128	-11	834	1,205	N/A
9/30/2020	7,065	-152	762	1,203	N/A
6/30/2020	7,028	37	899	1,399	N/A
3/31/2020	7,791	377	1,008	1,753	N/A
12/31/2019	7,982	1,132	865	1,586	N/A
9/30/2019	7,928	-90	830	1,542	N/A
6/30/2019	7,872	-359	750	1,448	N/A
3/31/2019	7,891	-308	N/A	1,541	N/A
12/31/2018	7,933	-379	N/A	1,747	N/A
9/30/2018	7,930	1,753	N/A	1,771	N/A
6/30/2018	7,907	1,690	N/A	1,750	N/A
3/31/2018	7,849	1,689	N/A	1,797	N/A
12/31/2017	7,803	1,814	N/A	1,582	N/A
9/30/2017	7,748	652	N/A	1,807	N/A
6/30/2017	7,768	712	N/A	1,696	N/A
3/31/2017	7,752	497	N/A	1,635	N/A
12/31/2016	7,668	306	N/A	1,632	N/A
9/30/2016	7,604	363	N/A	1,468	N/A
6/30/2016	7,534	227	N/A	1,214	N/A
3/31/2016	6,767	84	N/A	1,031	N/A
12/31/2015	5,998	147	N/A	850	N/A
9/30/2015	5,287	174	N/A	742	N/A
6/30/2015	4,631	325	N/A	899	N/A
3/31/2015	4,646	670	N/A	956	N/A
12/31/2014	4,673	720	N/A	1,061	N/A

アナリストによる今後の成長予測

収入対貯蓄率: ZBHの予測収益成長率 (年間15.9% ) は貯蓄率 ( 3.1% ) を上回っています。

収益対市場: ZBHの収益 ( 15.9% ) はUS市場 ( 15.4% ) よりも速いペースで成長すると予測されています。

高成長収益: ZBHの収益は増加すると予測されていますが、大幅には増加しません。

収益対市場: ZBHの収益 ( 5.1% ) US市場 ( 9.8% ) よりも低い成長が予測されています。

高い収益成長: ZBHの収益 ( 5.1% ) 20%よりも低い成長が予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: ZBHの自己資本利益率は、3年後には低くなると予測されています ( 13.9 %)。

成長企業の発掘

企業分析と財務データの現状

データ	最終更新日（UTC時間）
企業分析	2025/10/05 12:04
終値	2025/10/03 00:00
収益	2025/06/30
年間収益	2024/12/31

データソース

企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。

パッケージ	データ	タイムフレーム	米国ソース例
会社財務	10年	損益計算書キャッシュ・フロー計算書貸借対照表	SECフォーム10-K SECフォーム10-Q
アナリストのコンセンサス予想	+プラス3年	予想財務アナリストの目標株価	アナリストリサーチレポート Blue Matrix
市場価格	30年	株価配当、分割、措置	ICEマーケットデータ SECフォームS-1
所有権	10年	トップ株主インサイダー取引	SECフォーム4 SECフォーム13D
マネジメント	10年	リーダーシップ・チーム取締役会	SECフォーム10-K SECフォームDEF 14A
主な進展	10年	会社からのお知らせ	SECフォーム8-K

* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用^。

特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。

分析モデルとスノーフレーク

このレポートの作成に使用した分析モデルの詳細は、Githubページでご覧いただけます。また、レポートの使用方法に関するガイドや、Youtubeでのチュートリアルもご用意しています。

シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。

業界およびセクターの指標

私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。

アナリスト筋

Zimmer Biomet Holdings, Inc. 26 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、。アナリストの投稿は一日中更新されます。62

アナリスト	機関
David Toung	Argus Research Company
Stephan Gasteyger	Atlantic Equities LLP
Jeffrey Johnson	Baird

Zimmer Biomet Holdings 将来の成長

Future 基準チェック /26

主要情報

今後の成長に関する最新情報

Zimmer Biomet Holdings, Inc. Revises Earnings Guidance for the Full Year Ending December 31, 2025

Consensus EPS estimates increase by 11%

Price target decreased by 9.9% to US$110

Zimmer Biomet Holdings, Inc. Revises Earnings Guidance for the Year Ending December 31, 2025

Consensus EPS estimates fall by 14%

Zimmer Biomet Holdings, Inc. Provides Earnings Guidance for the Year Ending December 31, 2025

Recent updates

Zimmer Biomet Holdings, Inc. to Report Q3, 2025 Results on Nov 05, 2025

Zimmer Biomet Holdings, Inc. Announces the Pharmaceutical and Medical Devices Agency (PMDA) in Japan Approved the Itaperloc Complete and Ig7 Hip System

Upcoming dividend of US$0.24 per share

Zimmer Biomet Holdings, Inc. announced that it has received CHF 600 million in funding

Second quarter dividend of US$0.24 announced

Zimmer Biomet Holdings, Inc. Announces New Chief Medical Advisors to Help Improve Standard of Musculoskeletal Care

Zimmer Biomet Holdings, Inc. Announces Quarterly Cash Dividend forThird Quarter of 2025, Payable on or About October 31, 2025

Second quarter 2025 earnings: Revenues exceed analysts expectations while EPS lags behind

Zimmer Biomet Holdings, Inc. Revises Earnings Guidance for the Full Year Ending December 31, 2025

Here's Why Zimmer Biomet Holdings (NYSE:ZBH) Can Manage Its Debt Responsibly

Zimmer Biomet Q2 Preview: Combining Monogram Autonomous Robotics With ROSA

Zimmer Biomet Holdings, Inc. (NYSE:ZBH) agreed to acquire Monogram Technologies Inc. (NasdaqCM:MGRM) for $144 million.

Zimmer Biomet Holdings, Inc. to Report Q2, 2025 Results on Aug 07, 2025

Many Still Looking Away From Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Upcoming dividend of US$0.24 per share

Zimmer Biomet Holdings (NYSE:ZBH) Is Paying Out A Dividend Of $0.24

Treace Medical Concepts, Inc. Files Patent Infringement Suit Against Zimmer Biomet Holdings, Inc. and Paragon 28, Inc. to Protect Lapiplasty Bunion Technology

Zimmer Biomet Holdings' (NYSE:ZBH) Dividend Will Be $0.24

First quarter dividend of US$0.24 announced

Zimmer Biomet Holdings, Inc. Announces Quarterly Cash Dividend for Second Quarter of 2025, Payable on or About July 31, 2025

Zimmer Biomet Holdings (NYSE:ZBH) Shareholders Will Want The ROCE Trajectory To Continue

Consensus EPS estimates increase by 11%

Some May Be Optimistic About Zimmer Biomet Holdings' (NYSE:ZBH) Earnings

Price target decreased by 9.9% to US$110

Zimmer Biomet Holdings, Inc. Revises Earnings Guidance for the Year Ending December 31, 2025

First quarter 2025 earnings: EPS exceeds analyst expectations

Zimmer Biomet Holdings, Inc. (NYSE:ZBH) completed the acquisition of Paragon 28, Inc. (NYSE:FNA) from a group of shareholders.

Zimmer Biomet Holdings, Inc. to Report Q1, 2025 Results on May 05, 2025

An Intrinsic Calculation For Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Suggests It's 39% Undervalued

Zimmer Biomet Holdings, Inc., Annual General Meeting, May 29, 2025

Upcoming dividend of US$0.24 per share

Zimmer Biomet Holdings (NYSE:ZBH) Has Announced A Dividend Of $0.24

Zimmer Biomet Holdings, Inc. Highlights Diverse Portfolio of Orthopedic & Musculoskeletal Innovations At AAOS 2025 Annual Meeting

Zimmer Biomet Holdings, Inc. Appoints Kristen Cardillo as Senior Vice President, Chief Communications Officer, Effective March 10, 2025

Zimmer Biomet Holdings (NYSE:ZBH) Has Announced A Dividend Of $0.24

Fourth quarter dividend of US$0.24 announced

Zimmer Biomet Holdings, Inc. Appoints Jehanzeb Noor as Senior Vice President, Chief Strategy, Innovation and Business Development Officer

Zimmer Biomet Holdings, Inc. Approves Quarterly Cash Dividend for the First Quarter of 2025, Payable on or About April 30, 2025

COO, President exercised options and sold US$1.3m worth of stock

Consensus EPS estimates fall by 14%

New minor risk - Earnings quality

Zimmer Biomet: Adding To The Growth Profile

Full year 2024 earnings: EPS misses analyst expectations

Zimmer Biomet Holdings, Inc. Provides Earnings Guidance for the Year Ending December 31, 2025

Investors Appear Satisfied With Zimmer Biomet Holdings, Inc.'s (NYSE:ZBH) Prospects

Zimmer Biomet Holdings, Inc. (NYSE:ZBH) entered into a definitive agreement to acquire Paragon 28, Inc. (NYSE:FNA) for $1.1 billion

Zimmer Biomet Holdings, Inc. to Report Q4, 2024 Results on Feb 06, 2025

These 4 Measures Indicate That Zimmer Biomet Holdings (NYSE:ZBH) Is Using Debt Reasonably Well

Zimmer Biomet: Back On Offense With Strong Cash Flow Outlook

Zimmer Biomet Holdings (NYSE:ZBH) Is Due To Pay A Dividend Of $0.24

Third quarter dividend of US$0.24 announced

Zimmer Biomet Holdings, Inc. Announces Quarterly Cash Dividend for Fourth Quarter of 2024, Payable on or About January 31, 2025

Zimmer Biomet Holdings, Inc. Receives FDA Clearance for OsseoFit Stemless Shoulder System for Total Shoulder Replacement

At US$108, Is It Time To Put Zimmer Biomet Holdings, Inc. (NYSE:ZBH) On Your Watch List?

Zimmer Biomet Receives FDA Clearance for Persona SoluTion PPS Femur

Zimmer Biomet Holdings, Inc. Receives FDA Approval for Oxford Cementless Partial Knee, Only Cementless Partial Knee Replacement Implant in the U.S

Zimmer Biomet Holdings, Inc. Appoints Arnold Schwarzenegger as Chief Movement Officer

Shareholders Can Be Confident That Zimmer Biomet Holdings' (NYSE:ZBH) Earnings Are High Quality

Results: Zimmer Biomet Holdings, Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates

Zimmer Biomet Holdings, Inc. Updates Financial Guidance for the Ending December 31, 2024

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

Zimmer Biomet to Debut New Z1™ Femoral Hip System and Clinical Data on G7® Acetabular System at 2024 AAHKS Annual Meeting

Zimmer Biomet Holdings, Inc. to Report Q3, 2024 Results on Oct 30, 2024

Zimmer Biomet: The Undervalued Titan Of Joint Replacements

Upcoming dividend of US$0.24 per share

Zimmer Biomet Stock: Don't Jump In At The 52-Week Low

Zimmer Biomet Holdings, Inc. Appoints David Demartino as Senior Vice President, Investor Relations

Second quarter dividend of US$0.24 announced

Zimmer Biomet Announces Quarterly Dividend for Third Quarter of 2024, Payable on or About October 31, 2024